Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 51

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 51
---
center'>37</div>

For the nine months ended June 30 2025, the Company reported a net other expense of $(468,548) whereas in the same period ended 2024 the Company reported the net other expense of $(65,688). Net other expense was primarily driven by the recognition of a Derivative Expense in of $(376,312) in 2025. For the period ended June 30, 2025 the Company also recognized higher interest and amortization expenses as compared to the period ended 2024.

Net Loss

The Company recognized an Operating Loss of $215,486 during the nine months ended June 30, 2025 whereas the Company recognized an Operating Loss of $331,819 for the same period ended 2024. The reduction in operating loss is primarily attributable to a reduction in all expense categories other than General and Administrative expenses and rent incurred during the period ended 2025 as compared to the period ended in 2025.

Net Loss is $ 702,033 for the nine months ended June 30, 2025 as opposed to a Net Loss of $397,507 for the same period ended 2024. The difference is primarily attributable to the recognition by the Company of a Derivative Loss of $376,312 recognized in the period ended in 2025.

Working capital deficit increased by $598,321 from September 30, 2024 to June 30, 2025, primarily due to increase in Derivative Liability.

|                                                      |     | Nine Months ended 30-Jun |     2025 |   |     |   |     2024 |   |
|:-----------------------------------------------------|:----|:-------------------------|---------:|:--|:----|:--|---------:|:--|
| Net cash used in operating activities                |     | $                        | (241,500 | ) |     | $ | (544,247 | ) |
| Net cash provided by financing activities            |     |                          |  242,545 |   |     |   |  458,058 |   |
| Net increase (decrease) in cash and cash equivalents |     | $                        |    1,045 |   |     | $ |  (59,189 | ) |

Liquidity and Capital Resources

Operating Activities

Net cash used in operating activities for the nine months ended June 30, 2025 was $241,500, compared to $544,247, for the same